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BEAM (BCNU, etoposide, cytarabine, melphalan) is the most widely used high dose chemotherapy regimen for
autologous transplant in lymphoid malignancies. We report our early experience with an alternative regimen LEAM
where BCNU was replaced with the oral analogue CCNU (lomustine) to tide over the non-availability of BCNU. Fifty one
patients of relapsed or refractory lymphoma who received BEAM (n= 34) and LEAM (n= 17) from September 2001 to
February 2012 were analyzed. From October 2009 onwards LEAM was used as the conditioning regimen instead of
conventional BEAM. Patients in the LEAM group had more chemorefractory disease (35% vs 9%, p = 0.045) and high risk
comorbidity score (24% vs 0%, p = 0.019). Grade 3 and 4 oral mucositis (67.6% vs. 64.7%, p = 0.834) and diarrhea (47% vs.
41.1%, p = 0.691) were similar. No difference was noted between the two groups in terms of engraftment, documented
infections, antibiotic use, cumulative toxicity risk, length of hospital stay and 100 day transplant related mortality. The
estimated 2 year overall survival (61.7% vs. 62.7%, p = 0.928) and event free survival (44.6% vs. 41.1%, p = 0.510) of the
regimens BEAM and LEAM respectively were comparable. Thus LEAM appeared equivalent to BEAM in terms of toxicity
and efficacy and can be used as an alternative to BEAM.
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High dose chemotherapy (HDC) and autologous stem
cell transplantation (ASCT) is an established treatment
procedure and offers a chance for long-term disease
control in many patients with relapsed or refractory
Hodgkin’s lymphoma (HL) and Non Hodgkin’s lymph-
oma (NHL) (Appelbaum 2008). Several HDC regimens
with different drug combinations have been in use,
however, no randomized data is available to demon-
strate superiority of any one regimen and retrospective
comparative reports are sparse (Jo et al. 2008; Puig et al.
2006; Salar et al. 2001; Wang et al. 2004; Zaucha et al.
2008). Given the limited morbidity and comparable efficacy
of the BEAM (BCNU/Carmustine, etoposide, cyt rabine,
melphalan) protocol, which was designed to avoid the tox-
icities of Cyclophosphamide and total body irradiation, it
has become the most widely used conditioning regimen for
lymphoma transplants (Linch et al. 1997; Mills et al. 1995).
Lomustine (CCNU) based regimens have been used for
high dose chemotherapy conditioning (Perz et al. 2007;
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monary toxicity associated with BCNU (Stuart et al. 2001),
but few if any comparative studies exist (Kumar et al.
2009). Recently, there was a shortage of BCNU globally and
to overcome the situation we instead used a modified regi-
men LEAM, where BCNU was replaced with CCNU. In
this study we report the results of this alternative drug
schedule and compare it with the BEAM protocol, focusing
on early toxicities, infectious complications and transplant-
related mortality (TRM).Patients and methods
Patient selection
The study group consisted of adult patients with re-
lapsed or refractory lymphoma (NHL or HL) who were
treated with high dose chemotherapy (either BEAM or
LEAM) followed by autologous stem cell transplantation
in the Department of Medical Oncology at the Institute
Rotary Cancer Hospital, All India Institute of Medical
Sciences (New Delhi, India) between September 2001
and February 2012. In all, a total of 51 patients were an-
alyzed, 34 patients received BEAM and 17 patients re-
ceived LEAM.an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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Prior to transplant, patients were assessed for their clinical
and treatment history, previous chemotherapy received in-
cluding salvage therapy, pretransplant disease status, ECOG
performance status, laboratory parameters and organ func-
tions. Scores as per the hematopoietic cell transplant co-
morbidity index (HCT – CI) system (Sorror et al. 2005) for
comorbidity risk assessment were calculated for each pa-
tient from clinical records and documented pretransplant
laboratory evaluation and a score of 0 was assigned for ab-
sent information on a particular comorbidity. Growth factor
(G-CSF, granulocyte colony stimulating factor) mobilized
peripheral blood, which was harvested by leukapheresis,
was the source of stem cell rescue for all patients. High
dose chemotherapy regimen administered was BEAM in 34
patients and LEAM in 17 patients. Anti-emetic support in-
cluded aprepitant, ondansetron, and dexamethsone with
both the regimens. BEAM consisted of BCNU (carmustine)
300 mg/m2 (total dose) i.v. on day −6, etoposide 800
mg/m2 (total dose) i.v. divided over 4 days from days −5
to −2, ara-C (cytarabine) 1600 mg/m2 (total dose) i.v. twice
daily divided over 4 days from days −5 to −2, and melpha-
lan 140 mg/m2 (total dose) i.v. on day −1. LEAM consisted
of CCNU (Lomustine) 200mg/m2 p.o. on day −6, eto-
poside 800 mg/m2 (total dose) i.v. divided over 4 days from
days −5 to −2, ara-C (cytarabine) 1600 mg/m2 (total dose)
i.v. twice daily divided over 4 days from days −5 to −2, and
melphalan 140 mg/m2 (total dose) i.v. on day −1. We
cryopreserved stem cells in 18 patients and in 33 patients
stem cells were stored at 4°C. Following infusion of the
stem cell product (on day 0) after the end of conditioning,
all patients were observed for toxicities and febrile complica-
tions which were managed as per standard guidelines and
institutional protocol. All patients received growth factor
support starting on day 1 till the time of engraftment. Plate-
let and blood transfusion was given as required during the
course. All patients were treated as in-patients and remained
hospitalized until engraftment and till the time deemed clin-
ically suitable for discharge. Follow up information was col-
lected by review of out-patient follow up records and
patients were contacted through phone calls and letters.
Outcome evaluation and study definitions
For the purpose of analysis standard remission criteria were
applied to assess disease status following salvage chemo-
therapy, prior to HDC and transplant, and response beyond
30 days of transplant. Achievement of at least a PR after sal-
vage therapy was regarded as chemosensitive disease. Pa-
tients with progressive or refractory disease prior to
transplant were defined to have chemoresistant disease.
Neutrophil engraftment was defined as first of three con-
secutive days with achievement of absolute neutrophil
count of ≥ 500 /cm3 and no subsequent decline. Platelet en-
graftment was defined as first of three consecutive values ofplatelet count ≥ 20,000 /cm3 with transfusion independence
Standard definition for febrile neutropenia was used and fe-
brile episodes were classified according to IHS (Immuno-
compromised Host Society) consensus conference and the
ESCMID (European Society of Clinical Microbiology and
Infectious Diseases) guidelines into clinically documented
infections (CDI), microbiologically documented infections
(MDI) and fever of unknown origin (FUO) (Hughes et al.
1992; Pizzo et al. 1990). Regimen related organ toxicities,
evaluated in the first 100 days, were graded using the
Seattle criteria (Bearman et al. 1988). The maximum tox-
icity score was the highest score reached in any single organ
system. Cumulative toxicity score was the sum of the
highest score observed in each organ at any time. Length of
hospital stay (LOS) was defined as the time from the day of
infusion of stem cell product to the day of hospital dis-
charge. Transplant related mortality (TRM) was taken as
death from any cause other than disease relapse or progres-
sion occurring within the first 100 days after ASCT. Relapse
or progression was defined as worsening in the disease
status from that at the time of transplant or the start of a
new definitive therapy at any time after transplant. Overall
survival (OS) was measured from date of transplant to
death from any cause. Event free survival (EFS) was defined
from the day of transplant until death from any cause,
relapse or progression.
Statistical analysis
For evaluation and comparison of the early post transplant
outcomes between the two groups of patients, we used the
Fisher’s exact test for categorical variables and the Mann
Whitney U test/ independent sample t test for continuous
variables. OS and EFS were estimated using the Kaplan and
Meier method. Log-rank test was used to examine differ-
ences in survival curves. Median follow up time was calcu-
lated using the Kaplan Meier method for potential follow
up. Data were censored for survival analysis on 30th June
2012. SPSS v 16.0 was used for analysis.
Results
Patient characteristics
Out of a total of 51 patients included in the study, 26
patients had NHL and 25 patients had HL. The median
age of the study group was 33 years (range, 17 – 63
years) and the male to female ratio was 3.6:1. The me-
dian time from diagnosis to transplant for the whole co-
hort was 22.2 months (range, 1.9 – 144.1 months). The
patient characteristics at transplant are outlined in
Table 1 according to the high dose regimen. As the ana-
lysis was done retrospectively some differences were
noted between the two groups. Considerably more pa-
tients in the LEAM group than the BEAM group had
chemorefractory disease (35% vs 9% respectively, p =
0.045) and a high risk comorbidity score (24% vs 0%
Table 1 Patient characteristic pre-transplant





N % N % p
Median age
(range)
37 (17 – 63) 26 (18–59) 0.070
Sex 0.472
Male 28 82 12 71
Female 6 18 5 29
Diagnosis 0.771
NHL 18 53 8 47




1 3 9 3 18
2 14 41 7 41
≥ 3 17 50 7 41







Pre transplant disease status 0.074
CR 13 38 5 30
PR 18 53 6 35
Progressive/ refractory disease 3 9 6 35
Chemosensitivity 0.045
Chemosensitive disease 31 91 11 65
Chemorefractory disease 3 9 6 35
ECOG PS 0.650
0 – 1 28 85 16 94
≥ 2 5 15 1 6
HCT-CI 0.019
Low risk (0) 19 56 8 47
Intermediate risk (1 – 2) 15 44 5 29
High risk (≥ 3) 0 - 4 24
Median CD34 cell dose 2.3 x 106/kg 2.4 x 106/kg 0.536
Abbreviations: NHL, Non Hodgkin’s lymphoma; HL, Hodgkin’s lymphoma; Dx,
Diagnosis; CR, Complete remission; PR, Partial remission; ECOG PS, Eastern
Cooperative Oncology Group Performance Status; HCT-CI, Hematopoietic Cell
Transplant Co morbidity Index.
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features were comparable between the two groups.
Peri-transplant outcomes
We observed no significant difference in the peri-
transplant outcomes in terms of engraftment, febrile
complications, regimen related organ toxicities, intraven-
ous antibiotic use, duration of hospitalization and 100
days TRM between the two high dose regimens studied.
The early post transplant outcomes are summarized in
Table 2 in relation to the study subgroups.Engraftment
The median number of progenitor CD34+ cells harvested
were comparable in the two groups (p = 0.536) and the
time to neutrophil engraftment was similar (12 and 15 days
for BEAM and LEAM respectively, p = 0.090). The median
time to platelet recovery was also comparable (18.5 and 22
days for BEAM and LEAM respectively, p = 0.199).
Infectious complications
All patients developed neutropenic fever at a median of
3 days after the infusion of stem cell graft. The febrile
episodes were clinically documented in 29% (n = 15) pa-
tients, microbiologically documented in 39% (n = 20) pa-
tients and were without a defined focus in 32% (n = 16)
patients. There was no difference in the occurrence of
complicated infections between the two HDC sub-
groups. The number of broad spectrum antibiotics used
and median duration of antibiotic use were also compar-
able (p = 0.157 and 0.185 respectively) as shown in
Table 2.
Regimen related toxicities
The most common grade 3 or 4 organ toxicity was
mucositis and was observed in 67% patients in all,
followed by diarrhea in 45% patients. Distribution of
grade 3 or 4 mucositis and diarrhea in the two groups
were similar. Grade 4 pulmonary toxicity was observed
in 4 patients that was similarly distributed between the
two groups. Grade 3 or 4 hepatic toxicity was seen in 3
patients, all in the BEAM subgroup. No grade 3 or 4
renal toxicity was noted, however, grade 1 / 2 renal dys-
function occurred in 16 patients (31%) and was similarly
distributed in both the groups (p = 0.753). Cardiac tox-
icity (grade 1) was seen in only 1 patient with NHL in
the BEAM arm. Grade 3 or 4 CNS (Central nervous sys-
tem) toxicity was noted in 1 patient in the BEAM group.
Four patients had hemorrhagic cystitis, 3 in the BEAM
and 1 in the LEAM arm. However, the cumulative tox-
icity risk scores, calculated according to the Seattle cri-
teria as described, were equitably distributed between
the two study groups with comparable numbers in the
low, intermediate and high risk categories as shown in
Table 2. The median duration of hospitalization at 20
days and 25 days for the BEAM and the LEAM arms re-
spectively was also comparable (p = 0.414).
Transplant related mortality
TRM at 100 days occurred in 8 patients (15.6%), 6 pa-
tients (18%) died in the BEAM group and 2 (12%) pa-
tients died in the LEAM group (p = 0.703). Majority of
the patients (n = 7) died prior to neutrophil engraftment
and the causes for death were sepsis in 2 patients,
multiorgan dysfunction (primarily respiratory) in 4 pa-
tients and multifactorial (infections plus organ toxicities)
Table 2 Peritransplant outcomes


















FUO (Fever of unknown origin) 9 26.5 6 35.3
MDI (microbiologically
documented infection)
14 41.2 6 35.3
CDI (Clinically documented infection) 11 32.3 5 29.4





Antibiotic number† 4.9 ± 1.6 5.7 ± 2.3 0.157
Regimen related Organ toxicities
Oral mucositis (Grade 3/4) 23 68 11 65 0.834
Diarrhea (Grade 3/4) 16 47 7 41 0.691
Pulmonary dysfunction (Grade 3/4) 3 9 1 6 1.00
Cumulative toxicity risk score
(Seattle criteria)
Low risk (0 – 4) 22 65 13 76 0.448
Intermediate risk (5 – 8) 5 15 3 18
High risk (≥ 9) 7 20 1 6






Yes (died) 6 18 2 12 0.703
No (Alive) 28 82 15 88
* median values with range.
† mean number of antibiotics used per patient if a given antibiotic was used
intravenously for more than 48 hours.
‡ from day of infusion of stem cell graft to day of hospital discharge.
Figure 1 Kaplan Meier survival estimate for (a) Overall survival and (b
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due to multiorgan failure and sepsis. All four patients
who developed grade 4 pulmonary toxicity died.
Survival results
At a median follow up of 36.6 months (range, 0.26 – 130.9
months), the median OS for the whole cohort was 51.6
months and median EFS was 16.3 months. The estimated 5
year OS and EFS for the entire study group was 49.3% (SE
0.08) and 39.6% (SE 0.07) respectively. No significant differ-
ence was noted in the estimated 2 year OS [BEAM - 61.7%
(SE 0.08) vs. LEAM 62.7% (SE 0.12), p = 0.928] and EFS
[BEAM – 44.6% (SE 0.09) vs. LEAM – 41.1% (SE 0.11), p =
0.510)] between the two HDC study groups (Figure 1).
Discussion
High dose chemotherapy and ASCT for lymphomas utilizes
several drug combinations and in the absence of random-
ized comparative data, BEAM is the regimen most widely
used because of its apparent tolerability and established effi-
cacy. Shortage of old drugs is a worldwide problem, and
while alternative regimens do follow the principles of com-
bination chemotherapy, this requires attention and action by
our health authorities. BCNU needs an alcoholic solvent for
intravenous infusion and lately its availability world over was
stalled by technical problems in its production (Leslie 2009).
CCNU (lomustine) another nitrosurea, available for oral ad-
ministration seemed the most logical substitute, and the
modified regimen (LEAM) use was reported by some au-
thors (Perfetti et al. 2009; Ramzi et al. 2012). Moreover, in-
vestigators have used other lomustine based regimens
for high dose chemotherapy conditioning for lymph-
omas; partly in view of the concern for higher rates of
pulmonary toxicity associated with BCNU compared to
CCNU. LACE (lomustine, cytarabine (Ara-C), cyclo-
phosphamide, etoposide) (Perz et al. 2007) and CCNU
substitution for BCNU in the CBV (cyclophosphamide,
BCNU, etoposide) regimen (Stuart et al. 2001), are) Event free survival for patients treated with BEAM or LEAM.
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comparable results. However, randomized studies are
absent and direct comparative studies are lacking. In
this single centre study, we examined the toxicities and
efficacy of the recently used LEAM regimen and com-
pared it with standard BEAM.
We found no significant difference in the global measures
of peri-transplant outcomes in terms of engraftment, febrile
complications, regimen related organ toxicities, intravenous
antibiotic use, duration of hospitalization and 100 days
TRM between the two high dose regimens. Also there was
no difference in the short term survival and relapse/pro-
gression among the two groups.
Time to both neutrophil and platelet engraftments were
not significantly different in the two treatment schedules and
were comparable to that reported in the literature for BCNU
and CCNU based regimens (Perz et al. 2007; Puig et al.
2006). Similarly, documented infections were not different
between the groups. Gastrointestinal toxicity was the
commonest grade 3/4 toxicity with mucositis (67%) and diar-
rhea (45%) evenly distributed in both the groups. Similar
rates for mucositis have been reported for BCNU based regi-
mens (Mills et al. 1995; Wang et al. 2004). Although BCNU
is reported to have more pulmonary toxicity compared to
CCNU (Cordonnier et al. 1983; Reece et al. 1991), no signifi-
cant difference was seen in the occurrence of grade 3 or 4
pulmonary toxicity between the study groups (9% and 6%)
in the present cohort. In the study by Stuart et al. utilizing a
CCNU based regimen for relapsed HL (Stuart et al. 2001),
incidence of interstitial pneumonitis with high dose CCNU
exceeded prior studies with BCNU, 63% incidence of inter-
stitial pneumonitis (IP) compared to 25% to 28% reported
for BCNU at dose ≥ 600 mg/m2 (Schmitz et al. 1993;
Wheeler et al. 1990). The authors attributed this to the use
of a broader definition for IP, inclusion of patients with
preexisting IP and prior exposure to radiotherapy. Notably,
despite the fact that there were significantly more number of
patients with chemorefractory disease and high risk co mor-
bidity index in the LEAM subgroup, only 1 (6%) patient had
a high risk (≥ 9) cumulative toxicity score compared to 7
(20%) in the BEAM subgroup though the difference was not
significant.
In our study, 100 day TRM of 15.6% for the whole cohort
was a little higher than the currently reported figures glo-
bally (Sureda et al. 2001; Wang et al. 2004) however, the dif-
ference between the two groups was not significant. The
early survivals results for OS and EFS (estimated 2 years –
61.7% and 44.6% for BEAM and 62.7% and 41.1% for
LEAM respectively) at a median follow up of 36.6 months
are also similar for the two groups. In the report on LEAM
by Perfetti et al., at a median follow-up of 3.66 years OS
was 72% and disease free survival (DFS) was 66% (Perfetti,
et al. 2009). In another study of a similar regimen CEAM,
with a median follow-up of 27 months, median DFS was 20months and median OS was not reached (Ramzi et al.
2012). Equivalent results for patients in the LEAM subgroup
in our present study, even with more chemorefractory dis-
ease and high co morbidity index warrants further confirm-
ation in a randomized study with larger number of patients.
If this is confirmed it is possible that LEAMmay be superior
in chemosensitive disease.
With this study we document the initial comparative re-
sults in a small group of patients and conclude that the two
regimens, BEAM and LEAM are equivalent for early peri-
transplant outcomes and survival. And, lomustine can be a
cheaper and readily available alternative to BCNU.
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